News about Market

BAL Pharma posts Rs 700.71 M revenue for Q1FY23

BAL Pharma posts Rs 700.71 M revenue for Q1FY23

Revenue was impacted by macro and uncontrolled factors led by geopolitical concerns, external market turmoil and certain other unavoidable market factors

Market | 16/08/2022 | By Sudeep Soparkar

Cadila Pharmaceuticals creates ? Collaboration Vertical ? to drive synergies, growth

Cadila Pharmaceuticals creates ? Collaboration Vertical ? to drive synergies, growth

The new vertical will work in close collaboration with different verticals of the company and group

Market | 09/08/2022 | By Sudeep Soparkar 428

Sebi approves for Rs 600 crores IPO to Hexagon Nutrition

Sebi approves for Rs 600 crores IPO to Hexagon Nutrition

It said that the company had filed its draft prospectus in December 2021. The IPO consists of a fresh issue of shares worth Rs 100 crores and an Offer For Sale (OFS) of up to 30,113,918 equity shares, as per the company's Draft Red Herring Prospectus (DRHP)

Market | 08/03/2022 | By Darshana 144

Panacea Biotec's domestic formulation brands for India & Nepal bought by Mankind Pharma

Panacea Biotec's domestic formulation brands for India & Nepal bought by Mankind Pharma

Mankind Pharma Limited, India's 4th largest pharmaceutical company, announced that the company has entered into an agreement with Panacea Biotec to acquire the domestic formulations brands of PBPL for India and Nepal for Rs. 1,872 crore

Market | 01/03/2022 | By Darshana 199

Mankind Pharma enters into an agreement with Dr Reddy's Laboratories Ltd to acquire two of its brands Combihale and Daffy

Mankind Pharma enters into an agreement with Dr Reddy's Laboratories Ltd to acquire two of its brands Combihale and Daffy

Combihale is used for the treatment of asthma and chronic obstructive pulmonary disease. The market for this category is valued at ~ Rs. 900 crore growing at 14% (IQVIA). The acquisition of Combihale is expected to strengthen Mankind's presence in the inhalation respiratory market segment

Market | 16/02/2022 | By Darshana 129

JB Chemicals and Pharmaceuticals: revenue growth of 10 per cent

JB Chemicals and Pharmaceuticals: revenue growth of 10 per cent

JB Chemicals and Pharmaceuticals has announced its financial results for the third quarter ended 31st December, 2021. For the third quarter ended 31st December, 2021, the company recorded revenue of Rs 601 crores as compared to Rs 548 crores, registering a growth of 10 per cent over the corresponding quarter of the previous financial year

Market | 15/02/2022 | By Darshana 116

Cipla to acquire stake in solar power firm AMP Energy Green Eleven Pvt Ltd

Cipla to acquire stake in solar power firm AMP Energy Green Eleven Pvt Ltd

Cipla has entered into a shareholder's agreement along with the power purchase agreement to acquire up to 32.49 per cent stake on a fully diluted basis in AMP Energy Green Eleven.

Market | 08/02/2022 | By Darshana 109

Pharma Expert's take on Budget 2022

Pharma Expert's take on Budget 2022

While the government has increased overall budget expenditure for healthcare and pharma industry, industry people have many insights to share on what they think about the budget 2022

Market | 02/02/2022 | By Darshana 168

Budget 2022: Many offerings for Pharma and Healthcare sector

Budget 2022: Many offerings for Pharma and Healthcare sector

India proposed doubling healthcare spending in an annual budget unveiled on Monday and lifted caps on foreigners investing in its vast insurance market to help revive an economy that suffered its deepest recorded slump as a result of the pandemic

Market | 01/02/2022 | By Darshana 111

JB Chemicals and Pharmaceuticals to acquire brands from Sanzyme

JB Chemicals and Pharmaceuticals to acquire brands from Sanzyme

JB Chemicals and Pharmaceuticals yesterday announced that it will acquire brands for the India market from Sanzyme, a player in the probiotics and reproductive health segment in the country. The transaction is valued at approximately Rs 628 crores, and is expected to be completed in the next two weeks subject to customary closing formalities

Market | 27/01/2022 | By Darshana 160

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology